| Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity B Majumder, U Baraneedharan, S Thiyagarajan, P Radhakrishnan, ... Nature communications 6 (1), 6169, 2015 | 322 | 2015 |
| Preclinical cancer models and biomarkers for drug development: new technologies and emerging tools M Dhandapani, A Goldman Journal of molecular biomarkers & diagnosis 8 (5), 2017 | 56 | 2017 |
| Inhibition of rapamycin-induced AKT activation elicits differential antitumor response in head and neck cancers P Radhakrishnan, U Baraneedharan, S Veluchamy, M Dhandapani, ... Cancer research 73 (3), 1118-1127, 2013 | 27 | 2013 |
| Predicting tumor sensitivity to chemotherapeutic drugs in oral squamous cell carcinoma patients BM Robert, M Dakshinamoorthy, B Ganapathyagraharam Ramamoorthy, ... Scientific reports 8 (1), 15545, 2018 | 26 | 2018 |
| Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and Erbb2 N Brijwani, M Jain, M Dhandapani, F Zahed, P Mukhopadhyay, M Biswas, ... Scientific reports 7 (1), 1502, 2017 | 24 | 2017 |
| Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat Commun. 2015; 6: 6169 B Majumder, U Baraneedharan, S Thiyagarajan, P Radhakrishnan, ... Epub 2015/02/28. https://doi. org/10.1038/ncomms7169 PMID: 25721094, 0 | 6 | |
| Human tumor derived Oncoprint® platform predicts molecular mechanism of sensitivity and resistance to Fragmin in pancreatic cancer. M Sundaram, S Thiyagarajan, M Dhandapani, N Brijwani, A Prasath, ... Cancer Research 73 (8_Supplement), 5072-5072, 2013 | 1 | 2013 |
| PAT-1102, a novel HDAC inhibitor exhibits potent anti-tumor efficacy in patient-derived refractory solid tumors. P Radhakrishnan, M Dhandapani, B Ulaganathan, A Thayakumar, ... Cancer Research 73 (8_Supplement), 2051-2051, 2013 | 1 | 2013 |
| Mechanistic insights into the role of cAMP-regulated EPAC1 in tumor-induced angiogenesis and metastatic potential in triple-negative breast cancer M Dhandapani, A Goldman, N Kumar, P Prasad, E Jash, I Singh, ... Cancer Research 78 (13_Supplement), 2045-2045, 2018 | | 2018 |
| Application of patient tumors-derived tumor ecosystem platform for the development of novel HDAC inhibitor in solid cancers M Sundaram, B Ulaganathan, M Dhandapani, A Thayakumar, ... Cancer Research 74 (19_Supplement), 3736-3736, 2014 | | 2014 |
| Generation of primary cell lines from advanced colon cancer: a tool for screening novel anticancer molecules. R Nair, A Basu, M Dhandapani, B Majumder, B Ulaganathan Cancer Research 73 (8_Supplement), 2147-2147, 2013 | | 2013 |
| Primary human tumor-derived Oncoprint platform predicts molecular mechanism of sensitivity and resistance to anti-EGFR in colorectal cancer: A step towards personalized cancer … M Jain, F Zahed, A Prasath, M Dhandapani, S Veluchamy, A Kamal, ... Cancer Research 72 (8_Supplement), 3191-3191, 2012 | | 2012 |
Baraneedharan UlaganathanFounder, Rident Biosciences在 ridentbio.com 的电子邮件经过验证
